Skip to main
NRIX
NRIX logo

NRIX Stock Forecast & Price Target

NRIX Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Nurix Therapeutics Inc. has demonstrated a robust improvement in safety metrics for its drug candidates, with significant reductions in the prevalence of adverse events, enhancing the overall therapeutic profile of its pipeline drugs, particularly NX-5948 and NX-2127. The company’s progressing data and increasing study size indicate a favorable tolerability profile, supporting the potential for combination therapies in first-line and second-line settings for chronic lymphoblastic leukemia (CLL). With an estimated trajectory for potential accelerated approval by 2028 and a competitive edge in the treatment of triple-exposed CLL, the evolving data presents a compelling case for a positive market outlook for Nurix Therapeutics.

Bears say

Nurix Therapeutics Inc's stock outlook is negatively influenced by significant concerns regarding its clinical development trajectory and partnerships with major pharmaceutical companies. The company has experienced a decrease in median follow-up time for its candidates, which raises uncertainty about their effectiveness, as the duration of response has not been established. Additionally, the potential failure to successfully advance its DELigase platform and generate viable clinical candidates compounds the risks associated with its oncology pipeline, which may not be fully appreciated by the market.

NRIX has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nurix Therapeutics, Inc (NRIX) Forecast

Analysts have given NRIX a Buy based on their latest research and market trends.

According to 16 analysts, NRIX has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nurix Therapeutics, Inc (NRIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.